Using image-guided biopsies to understand resistance in advanced prostate cancer treatment
Official title: Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer to Identify Mechanisms of Resistance in Patients Undergoing 177Lu-PSMA Radioligand Therapy
Run by Jonsson Comprehensive Cancer Center · NCT05398302 · Data updated 2026-11-12
This study is testing how advanced imaging can help doctors understand why some men with hard-to-treat prostate cancer don't respond to a specific therapy, so they can find better treatment options.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Sex | Men only |
| Enrollment | 30 (estimated) |
| Sponsor | Jonsson Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Status | Recruiting |
| Started | April 26, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | June 15, 2026 |
| Trial ID | NCT05398302 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with histologically confirmed metastatic castration-resistant prostate cancer who are eligible for 177Lu-PSMA-617 therapy.
✕Probably not a fit
Patients with non-metastatic prostate cancer or those not eligible for 177Lu-PSMA-617 therapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the mechanisms of resistance to 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer. It employs image-guided biopsies to collect tumor samples before and after treatment, allowing for detailed analysis of molecular and cellular changes. The study aims to assess alterations in tumor, immune, and stromal cells through various advanced techniques, including histopathology and RNA sequencing. By understanding these mechanisms, the trial seeks to improve treatment strategies for affected patients.
Why it matters
Potential benefit: If successful, this study could lead to more effective treatment plans for patients with advanced prostate cancer by identifying resistance mechanisms.
How similar studies have gone: Other studies have shown promise in using image-guided biopsies to assess treatment responses, making this approach both relevant and potentially impactful.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Volunteer patient * Histologically confirmed prostate cancer * Eligible for 177Lu-PSMA-617 under expanded access protocol (IRB# 21-5010) or as part of an approved trial * Based on positron emission tomography (PET)/computed tomography (CT) images: Evidence of lymph node or soft tissue metastatic disease amenable to image-guided biopsy * Platelets \> 75,000/ul within 14 days prior to biopsy * Prothrombin time (PT) or International normalized ratio (INR) and a partial thromboplastin time (PTT) \< 1.5 times the institutional upper limit normal (ULN) within 14 days prior to biopsy * Patients on warfarin, aspirin, or other anti-coagulants are eligible provided they are deemed able to tolerate discontinuation of anti-coagulation for one week prior to the biopsy. Conversion to low molecular weight heparin prior to biopsy is permitted per local standard operating procedures, provided there is agreement regarding the procedure between the treating physician, the interventional radiologist and the principal investigator (PI) Exclusion Criteria: * Patients with significant congenital or acquired bleeding disorders (e.g. von Wildebrand's disease, acquired bleeding factor inhibitors) are not eligible
Where it's running
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States Recruiting
Study contacts
- Principal investigator: Johannes Czernin — UCLA / Jonsson Comprehensive Cancer Center
- Study coordinator: Ankush Sachdeva
- Email: asachdeva@mednet.ucla.edu
- Phone: 310-794-3421
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Combining cryoablation and radiation therapy for painful bone metastases
This study is testing if combining a freezing treatment with radiation can help people with painful bone cancer feel better compared to just using radiation alone.
-
CAR-T cell therapy with or without radiation for advanced prostate cancer
This study is testing if a new CAR-T cell therapy, with or without radiation, can help people with advanced prostate cancer live longer and feel better.
-
Using abemaciclib before a radioactive treatment for advanced prostate cancer
This study is testing if taking abemaciclib before a radioactive treatment can help men with advanced prostate cancer feel better and improve their treatment results.
-
Investigating DNA Repair and Radium-223 in Advanced Prostate Cancer
This study is testing if radium-223 can help people with advanced prostate cancer that has spread to the bones, while also looking at how changes in DNA repair might affect the treatment's success.
-
Using 18F-TRX to image solid tumors
This trial tests whether the 18F-TRX PET tracer can detect tumors in adults with advanced solid tumors such as high‑grade glioma, clear cell renal cell carcinoma, or metastatic castration‑resistant prostate cancer.
-
Targeted treatment for advanced prostate cancer
This study is testing whether using genetic testing to guide treatment can help people with advanced prostate cancer respond better to new medications.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.